13.2 Pelvic Inflammatory Disease & Gynecological Conditions

Pelvic Inflammatory Disease & Gynecological Conditions

Gynecological disorders represent a substantial proportion of outpatient consultations and emergency admissions in Kenyan primary healthcare centers (Level 3) and county referral hospitals (Level 4 and 5). Among these, Pelvic Inflammatory Disease (PID), ectopic pregnancy, and cervical neoplasia demand rigorous diagnostic acuity. Untreated or mismanaged upper genital tract infections directly cause devastating long-term reproductive sequelae, including tubal factor infertility, chronic pelvic pain, and life-threatening ruptured ectopic gestations.

---

1. Pelvic Inflammatory Disease (PID)

Pathophysiology & Etiology

Pelvic Inflammatory Disease (PID) refers to an ascending spectrum of inflammatory and infectious disorders affecting the upper female genital tract, encompassing any combination of endometritis, salpingitis, oophoritis, tubo-ovarian abscess (TOA), and pelvic peritonitis. Infection ascends through the endocervical canal into the sterile endometrial cavity and Fallopian tubes, frequently spilling into the peritoneal cavity.

PATHOGENS IMPLICATED IN ASCENDING PID:

1. Sexually Transmitted Primary Initiators:
   • Neisseria gonorrhoeae: Intracellular Gram-negative diplococcus causing rapid,
     destructive mucosal purulence and high fever.
   • Chlamydia trachomatis: Obligate intracellular pathogen causing insidious,
     subclinical, or 'silent' salpingitis with severe tubal scarring and mucosal damage.

2. Secondary Endogenous Invaders (Polymicrobial Overgrowth):
   • Anaerobes: Bacteroides fragilis, Prevotella species, Peptostreptococcus.
   • Bacterial Vaginosis-associated Flora: Gardnerella vaginalis, Atopobium vaginae.
   • Genital Mycoplasmas: Mycoplasma genitalium, Ureaplasma urealyticum.
   • Enteric Gram-Negative Bacilli: Escherichia coli, Klebsiella species.

Risk Factors

• Age < 25 years and sexually active (larger cervical ectopy facilitating pathogen binding).
• Multiple sexual partners or a new sexual partner within the past 30 to 60 days.
• Inconsistent or non-use of barrier contraception (male/female condoms).
• History of previous episodes of PID or documented sexually transmitted infections (STIs).
• Recent intrauterine instrumentation: Intrauterine Device (IUD) insertion within the preceding 3 weeks (the transient risk is associated with the insertion procedure dragging cervical flora into the cavity, NOT the IUD itself thereafter), dilation and curettage, or manual vacuum aspiration.
• Vaginal douching (disrupts protective lactobacilli flora and forces fluid upward).

Diagnostic Criteria (Kenya MOH / CDC Guidelines)

Because clinical presentation ranges from asymptomatic or indolent discomfort to life-threatening generalized peritonitis, and because the sequelae of untreated PID are catastrophic, diagnostic thresholds are intentionally kept broad. Clinicians must initiate empirical antimicrobial therapy in any young, sexually active woman presenting with lower pelvic pain if no other cause is identified and at least one minimum criterion is present on bimanual pelvic examination.

DIAGNOSTIC FRAMEWORK FOR PELVIC INFLAMMATORY DISEASE:

[Minimum Clinical Criteria (At least ONE must be present on bimanual exam)]
  ├── 1. Cervical Motion Tenderness ("Chandelier Sign" - exquisite pain on moving cervix)
  ├── 2. Uterine Tenderness (fundal tenderness on palpation)
  └── 3. Adnexal Tenderness (unilateral or bilateral adnexal discomfort)
         │
         ▼
[Supportive Criteria (Enhance Diagnostic Specificity)]
  ├── Oral temperature > 38.3°C (> 101°F)
  ├── Abnormal cervical mucopurulent discharge or cervical friability on speculum exam
  ├── Abundant white blood cells (leukocytes) on saline wet mount of vaginal secretions
  ├── Elevated Erythrocyte Sedimentation Rate (ESR) or C-Reactive Protein (CRP)
  └── Laboratory documentation of cervical N. gonorrhoeae or C. trachomatis (NAAT / culture)
         │
         ▼
[Definitive Criteria (Advanced Investigations)]
  ├── Endometrial biopsy demonstrating histopathological evidence of endometritis
  ├── Transvaginal ultrasound or MRI showing thickened, fluid-filled tubes (hydrosalpinx/pyosalpinx),
  │   free pelvic fluid, or tubo-ovarian complex/abscess
  └── Laparoscopic confirmation (gold standard: tubal erythema, edema, and purulent exudate)

Perihepatitis (Fitz-Hugh-Curtis Syndrome)

In approximately 5% to 15% of women with PID (particularly Chlamydia and Gonorrhea infections), purulent exudate travels via the right paracolic gutter to the subphrenic space, causing inflammation of the liver capsule and adjacent peritoneal surfaces (perihepatitis). Patients present with sharp, pleuritic, right upper quadrant (RUQ) abdominal pain radiating to the right shoulder, mimicking acute cholecystitis, pleurisy, or viral hepatitis. Liver enzymes are typically normal or only mildly elevated. Laparoscopy or laparotomy reveals classic "violin-string" fibrous adhesions spanning between the anterior liver capsule and the anterior abdominal wall or inferior diaphragm.

---

2. Management of Pelvic Inflammatory Disease

Outpatient Treatment Protocol (Mild to Moderate PID)

Outpatient therapy is appropriate for women who are hemodynamically stable, tolerating oral fluids, have no clinical features of peritonitis or abscess, and have a negative pregnancy test.

KENYA NATIONAL OUTPATIENT SYNDROMIC REGIMEN FOR PID:

  1. Ceftriaxone: 500 mg IM as a single dose stat
     (Covers Neisseria gonorrhoeae; administer 1 g IM if body weight ≥ 150 kg)
                         PLUS
  2. Doxycycline: 100 mg orally twice daily for 14 days
     (Covers Chlamydia trachomatis and Mycoplasma genitalium)
                         PLUS
  3. Metronidazole: 400 mg to 500 mg orally twice daily for 14 days
     (Covers anaerobes and co-existing Trichomonas vaginalis / bacterial vaginosis)

Critical Outpatient Practice Rules:

• 72-Hour Clinical Review: The patient must return for clinical reassessment within 72 hours. If there is no substantial improvement (persistent fever, worsening pelvic pain, new nausea or vomiting), she must be admitted immediately for parenteral therapy and pelvic imaging.
• Sex Partner Notification & Treatment: All sexual partners within the preceding 60 days must be evaluated and presumptively treated for gonorrhea and chlamydia (e.g., Ceftriaxone 500 mg IM stat + Doxycycline 100 mg bd for 7 days), regardless of whether they have symptoms. The couple must abstain from sexual intercourse until both partners have fully completed therapy and symptoms have completely resolved.

Indications for Inpatient Admission & Parenteral Therapy

Patients must be admitted to the gynecological ward for inpatient intravenous therapy if any of the following criteria are met:

• Inability to exclude surgical emergencies (e.g., acute appendicitis, ruptured ectopic pregnancy, ovarian torsion).
• Presence of a documented or suspected Tubo-Ovarian Abscess (TOA).
• Pregnancy (systemic PID in pregnancy is exceptionally rare but carries immense maternal-fetal morbidity).
• Severe systemic illness: high fever (temperature > 38.5°C), persistent nausea, intractable vomiting, or clinical signs of pelvic peritonitis.
• Failure of outpatient oral therapy after 72 hours.
• Inability to tolerate, absorb, or adhere to an outpatient oral regimen.

Inpatient Treatment Regimens

• Inpatient Regimen A: Ceftriaxone 1 g to 2 g IV once daily PLUS oral/IV Doxycycline 100 mg every 12 hours PLUS IV Metronidazole 500 mg every 8 hours.
• Inpatient Regimen B: IV Clindamycin 900 mg every 8 hours PLUS IV Gentamicin (loading dose 2 mg/kg, then maintenance 1.5 mg/kg every 8 hours or 5 mg/kg once daily).
• Step-down rule: Continue parenteral antibiotics until at least 24 to 48 hours after substantial clinical improvement (defervescence, reduced abdominal tenderness), then switch to oral Doxycycline 100 mg twice daily + Metronidazole 400 mg twice daily to complete a full 14-day course.

Long-Term Complications of PID

Failure to diagnose or adequately treat PID leads to permanent, irreversible structural damage:

• Tubal Factor Infertility: Rate of involuntary infertility is ~12% after a single episode of salpingitis, ~25% after two episodes, and exceeds 50% after three or more episodes due to post-inflammatory tubal occlusion and loss of endosalpingeal ciliated cells.
• Ectopic Pregnancy: Women with a history of PID experience a 7- to 10-fold increase in the risk of subsequent ectopic pregnancy due to intratubal synechiae and impaired ciliary motility trapping the fertilized ovum.
• Chronic Pelvic Pain: Affects up to 30% of women following PID, resulting from dense pelvic peritoneal adhesions, ovarian entrapment, and recurrent inflammation.
• Recurrent PID: Damaged Fallopian architecture creates susceptibility to repeated ascending bacterial infections.

---

3. Ectopic Pregnancy

Anatomy & Etiology

An ectopic pregnancy occurs when a fertilized blastocyst implants anywhere outside the normal endometrial lining of the uterine cavity. More than 95% of ectopic pregnancies occur in the Fallopian tube.

Major Risk Factors

• Prior history of ectopic pregnancy (recurrence risk is 10% to 15% after one episode, > 25% after two).
• Previous pelvic inflammatory disease or documented chlamydial/gonococcal salpingitis.
• History of tubal reconstructive surgery or previous bilateral tubal ligation (BTL failure).
• Intrauterine device (IUD) in situ: While IUDs provide excellent overall protection against all pregnancies, if a woman does conceive with an IUD in place, up to 50% of such gestations are ectopic.
• Assisted reproductive technologies (in vitro fertilization [IVF], embryo transfer).
• Documented pelvic endometriosis or extensive pelvic adhesions.

Clinical Presentation: The Classic Diagnostic Triad

Every female patient of reproductive age presenting with acute or subacute lower abdominal pain is considered to have an ectopic pregnancy until proven otherwise.

CLASSIC DIAGNOSTIC TRIAD OF ECTOPIC PREGNANCY:

  ┌──────────────────────────────────────────────────────────────┐
  │ 1. Amenorrhea (6 to 8 weeks since last normal menstrual period)│
  │ 2. Unilateral or Bilateral Lower Abdominal / Pelvic Pain      │
  │ 3. Abnormal Vaginal Bleeding (Light spotting / dark 'prune juice')│
  └──────────────────────────────────────────────────────────────┘

Note on Vaginal Bleeding: The abnormal bleeding is typically light, intermittent, dark brown ("prune-juice"), arising not from the tube itself, but from the breakdown and sloughing of the hormonally unsupported uterine decidual lining (decidual cast).

Ruptured Ectopic Pregnancy: Surgical Emergency

Tubal rupture produces rapid, life-threatening internal hemoperitoneum:

• Sudden, Sharp, Lancinating Pain: Sudden tearing lower abdominal pain that rapidly becomes generalized across the lower quadrants.
• Shoulder Tip Pain (Kehr's Sign): Blood pooling in the peritoneal cavity tracks up into the subdiaphragmatic spaces, irritating the diaphragmatic peritoneum. Because the diaphragm is innervated by the phrenic nerve (cervical roots C3, C4, C5), sensory pain is referred to the supraclavicular dermatomes at the right or left shoulder tip. Shoulder tip pain worsens on lying supine and is a pathognomonic sign of massive hemoperitoneum (typically > 500–1000 mL).
• Peritonism: Severe abdominal distension, involuntary muscular guarding, and sharp rebound tenderness.
• Hypovolemic Shock: Hypotension (BP < 90/60 mmHg), marked tachycardia (pulse > 110–130 bpm, weak/thready), tachypnea, profound pallor, cold clammy extremities, syncope, and restlessness.
• Pelvic Examination: Exquisite cervical motion tenderness; full, bulging, exquisitely tender Pouch of Douglas (boggy cul-de-sac) caused by pooled blood.

Diagnostic Protocols

1. Urine Beta-hCG: Rapid point-of-care pregnancy test is positive in > 99% of ectopic pregnancies.
2. Quantitative Serum Beta-hCG & The Discriminatory Zone:
   • The discriminatory zone is the serum beta-hCG concentration above which an intrauterine gestational sac MUST be reliably visualized on ultrasound.
   • On Transvaginal Ultrasound (TVS), the discriminatory threshold is 1,500 to 2,000 IU/L.
   • If serum beta-hCG is ≥ 2,000 IU/L and TVS shows an empty uterine cavity, an ectopic pregnancy is virtually confirmed.
   • In normal viable intrauterine pregnancy, serum beta-hCG increases by at least 35% to 53% every 48 hours; suboptimal rise or plateau suggests non-viable or ectopic gestation.
3. Bedside Pelvic Ultrasound Findings:
   • Empty uterine cavity with thickened decidua (or a central fluid collection termed a pseudogestational sac lacking the double decidual sign).
   • Complex, heterogeneous adnexal mass separate from the ovary (tubal ring sign: an echogenic ring surrounding an unruptured gestational sac).
   • Identification of an extrauterine live embryo with cardiac activity (confirms diagnosis in 15%–20%).
   • Free peritoneal fluid in the Pouch of Douglas (echogenic fluid with debris indicating blood) or in Morrison's pouch (hepatorenal space), indicating hemoperitoneum > 1 liter.
4. Culdocentesis:
   • A bedside diagnostic procedure performed in resource-limited primary health centers where emergency ultrasound is unavailable.
   • A 16G or 18G needle attached to a syringe is inserted through the posterior vaginal fornix into the Pouch of Douglas.
   • Positive Result: Aspiration of non-clotting dark blood (blood that has pooled in the peritoneum is defibrinated and does not clot in the syringe). Confirms active intraperitoneal bleeding / hemoperitoneum.
   • If aspirated blood clots in the syringe, a pelvic vein was accidentally punctured (traumatic tap).

Emergency Management of Ruptured Ectopic Pregnancy

RESUSCITATION & SURGICAL MANAGEMENT OF RUPTURED ECTOPIC:

[Immediate Resuscitation (Conducted Concurrently with Theatre Preparation)]
  ├── Place patient in supine or slight Trendelenburg position; administer high-flow oxygen (8-10 L/min)
  ├── Establish 2 wide-bore IV lines (16G or 14G cannulae)
  ├── Rapidly infuse IV crystalloids (Normal Saline or Ringer's Lactate) to maintain systolic BP ≥ 90 mmHg
  ├── Urgent Blood Draw: Group and Crossmatch 2 to 4 units of whole blood / packed RBCs, Hb/Hct, beta-hCG
  ├── Insert indwelling Foley catheter to monitor renal perfusion
  └── DO NOT DELAY SURGERY for complete fluid correction: Active bleeding cannot be corrected with fluids
         │
         ▼
[Emergency Exploratory Laparotomy]
  ├── Incision: Transverse suprapubic (Pfannenstiel) or midline infraumbilical incision
  ├── Rapidly exteriorize the uterus and identify the affected Fallopian tube
  ├── Immediate Hemostasis: Apply hemostatic forceps (Pemberton / Kocher clamps) across the mesosalpinx
  │   and the cornual junction to immediately halt maternal exsanguination
  ├── Salpingectomy: Excise the ruptured Fallopian tube, ligating vascular pedicles securely
  ├── Evacuate hemoperitoneum (suction/scoop blood clots) and inspect contralateral adnexa
  └── Check Rhesus status: Administer Anti-D Immunoglobulin (300 mcg IM) if mother is Rh-negative!

---

4. Cervical Cancer Screening (Kenya National Guidelines)

Epidemiology & Pathogenesis

Cervical cancer is the leading cause of cancer-related mortality among women in Kenya and the second most common female malignancy after breast cancer. Invasive cervical carcinoma is preceded by a prolonged, asymptomatic premalignant phase of Cervical Intraepithelial Neoplasia (CIN 1, CIN 2, CIN 3 / High-Grade Squamous Intraepithelial Lesions [HSIL]), providing an exceptional opportunity for effective screening and curative secondary prevention.

• Etiology: Persistent infection with oncogenic high-risk Human Papillomavirus (hr-HPV) genotypes, particularly HPV-16 and HPV-18 (responsible for > 70% of cervical cancers globally and in Kenya), as well as types 31, 33, 35, 45, 52, and 58. HPV oncoproteins E6 (which binds and degrades tumor suppressor p53) and E7 (which inactivates retinoblastoma protein pRb) drive dysregulated cellular proliferation.
• Cofactors: Early sexual debut, high parity, multiple sexual partners, tobacco smoking, immunosuppression (HIV infection markedly increases HPV persistence, recurrence, and rapid malignant transformation).

Screening Modalities in the Kenya Health System

Target Age & National Screening Intervals

According to the Kenya National Cancer Screening Guidelines:

• Target Population: All women aged 25 to 49 years (or from 21 years if high risk / early sexual debut).
• General Population (HIV-Negative): Screen every 5 years if the initial screening result is negative.
• HIV-Positive Women: Because HIV impairs host immunity against HPV, accelerating progression from pre-invasive lesions to invasive cancer, HIV-positive women must be screened every 3 years (or annually if initial screen or abnormal findings), commencing as soon as HIV diagnosis is established and sexual activity has occurred, regardless of chronological age.

Management of Precancerous Lesions: Screen-and-Treat Framework

When a precancerous lesion (positive VIA/VILI) is identified, management depends on lesion characteristics:

• Thermal Ablation (Thermocoagulation) or Cryotherapy: Indicated if the lesion involves < 75% of the cervix, is entirely located on the ectocervix, does not extend into the endocervical canal, has no suspicion of invasive cancer, and the transformation zone is fully visible. Can be performed immediately as outpatient single-visit care.
• Excisional Treatment (LEEP / LLETZ or Cold Knife Conization): Indicated if the lesion covers > 75% of the cervix, extends into the endocervical canal, has suspicious features of invasive cancer, or if the transformation zone is not fully visualized. Tissue specimen is submitted for formal histopathology.